Three Factors That Underlie Our Strengths

We have been working to realize regenerative medicine since 1999.
J-TEC obtained marketing approval for autologous cultured epidermis using patients' own cells in October 2007. It has been covered by health insurance since January 2009. At a time when only pharmaceutical products and medical devices were available in Japan, we developed unprecedented regenerative medical products using patients' cells. Autologous cultured epidermis was the first regenerative medical product in Japan and the unmistakable fruit of our sweat and tears.
We have now supplied regenerative medical products to more than 2500 patients and have increased our development strength, production capacity, and sales capacity as a top runner in regenerative medicine. We continue to strive every day to confront various challenges and realize new treatments using trial and error and experience.

When it comes to making products cultured from patients' cells, the most important thing is to ensure outstanding quality and deliver safe products to patients. Our production sites perform repeated training and strive for product quality control and safety control on a daily basis so that patients can receive treatments using J-TEC products with peace of mind. As a manufacturer of regenerative medical products, we have put systems in place to enable us to respond to sudden orders without knowing when a patient need may arise.
We have also built trust with physicians at medical institutions that use the regenerative medical products we supply. What kind of patients are our products for? Is the treatment prior to use OK with this, and what sort of care is recommended after use? We are diligent about listening to the physicians who use our products and also communicate with other physicians. It goes without saying that we also ask for the opinions of patients who have undergone treatment via their physicians. We believe that such activities contribute to the spread of regenerative medical products.
We deal with products that use patients' own cells. The examinations required to launch a product in an unprecedented new field are not easy, and we collaborated closely and held extensive discussions with the staff of the Japanese regulatory agency. Thorough efforts in activities such as postmarketing surveys of regenerative medical products helped to build trust with the regulatory agency.
While building trust with many people, we have contributed to the creation of fundamental structures for the development of regenerative medicine and worked to contribute to the development of regenerative medicine in Japan.

J-TEC has now obtained marketing approval for three regenerative medical products (autologous cultured epidermis, autologous cultured cartilage, and autologous cultured corneal epithelium) and is marketing them on the basis of insurance coverage. We have established culturing technology to produce regenerative medical products that meet fixed standards from different cells such as epidermis, cartilage, and cornea and cells with different growth methods for individual patients (with inconsistent raw materials). What we have had most experience in is producing high-grade materials using patients' cells, and as an autologous cell platformer, we have built a model in which regenerative medical products that use patients' own cells are supplied in a stable fashion.
In future, we will strive to use our accumulated knowledge and know-how to develop new products for the treatment of diseases of concern to many patients such as leukoderma and knee osteoarthritis.